Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration
Comparison in people · 2021
- What was studied
- 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
- Main finding
- Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Visual acuity · Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.
Reported findings and study design
Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.
Population or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity | Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04. | |
| Electroretinogram a-wave amplitude | Retinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV. | |
| Electroretinogram b-wave amplitude | Retinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV. |
The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated.
- The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified.
- The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.
Source details
Original journal report
Original Russian article, treatment methods and Tables 1 and 2.
Sources checked
Citation
A. V. Derkach, S. V. Trofimova. Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration Vrach. 2021;32(5):85–87.
Study source ↗ · DOI 10.29296/25877305-2021-05-16 · Bibliography entry · Link to this summary
Related compounds
Retinalamin
A retinal tissue polypeptide extract studied in people with retinal disease, including age-related macular degeneration and pigmentary retinal dystrophy. Studies distinguish injected Retinalamin from oral Normophthal.
Cortexin
A polypeptide extract of animal cerebral cortex. Its active material is a mixture of low-molecular-weight peptides studied in neurological rehabilitation, stroke and pediatric neurology.
Ventfort
A peptide mixture extracted from animal aorta, described in Russian reports on blood vessels and in dental patent cases.